This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Retain Universal Health (UHS) Stock Now
by Zacks Equity Research
Increased admissions at both of its operating segments, constant initiatives to bolster its care network and adequate cash generation abilities are likely to drive Universal Health (UHS).
Encompass Health's (EHC) Nationwide Hospital Count Rises to 147
by Zacks Equity Research
Encompass Health (EHC) opens a 60-bed inpatient rehabilitation hospital in Illinois, sustaining its aim to offer enhanced rehabilitation services throughout the United States.
Molina Healthcare (MOH) Up 32% in a Year: Is More Upside Left?
by Zacks Equity Research
Continued revenue growth, well-performing Medicaid and Medicare businesses, expense saving initiatives and solid cash balance continue to drive Molina Healthcare (MOH).
Applied Therapeutics Inc. (APLT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Applied Therapeutics Inc. (APLT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) closed at $22.86 in the latest trading session, marking a -0.95% move from the prior day.
Applied Therapeutics Inc. (APLT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) closed at $20.02 in the latest trading session, marking a +0.05% move from the prior day.
Applied Therapeutics Inc. (APLT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Applied Therapeutics Inc. (APLT) closed at $24.36, marking a +1.71% move from the previous day.
New Strong Sell Stocks for August 17th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Applied Therapeutics Inc. (APLT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Applied Therapeutics Inc. (APLT) closed at $25.93, marking a +0.5% move from the previous day.
Ultragenyx (RARE) Loss Narrows Y/Y & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.
Alexion (ALXN) Beats on Q2 Earnings & Sales, Ups '20 Guidance
by Zacks Equity Research
Alexion (ALXN) beats on earnings and sales in the second quarter of 2020.
Dr. Reddy's (RDY) Q1 Earnings Decline Y/Y, Sales Increase
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and revenues decline year over year in first-quarter fiscal 2021.
Alkermes' (ALKS) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.
Applied Therapeutics Inc. (APLT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) closed the most recent trading day at $25.74, moving +1.74% from the previous trading session.
What to Expect for Applied Therapeutics (APLT) Q2 Earnings
by Zacks Equity Research
During Applied Therapeutics' (APLT) upcoming Q2 earnings call, investor focus will be on the company's progress with its novel pipeline candidates targeting areas of high unmet medical need.
Zacks.com featured highlights include: Applied Therapeutics, Green Brick Partners, Frequency Therapeutics and Kelly Services
by Zacks Equity Research
Zacks.com featured highlights include: Applied Therapeutics, Green Brick Partners, Frequency Therapeutics and Kelly Services
LogicBio Therapeutics (LOGC) Catches Eye: Stock Jumps 7.1%
by Zacks Equity Research
LogicBio Therapeutics (LOGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
4 Stocks to Make the Most of New Analyst Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for these stocks.
Applied Therapeutics Inc. (APLT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Applied Therapeutics Inc. (APLT) closed the most recent trading day at $28.36, moving +0.32% from the previous trading session.
Moderna (MRNA) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Moderna (MRNA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Principia Biopharma (PRNB) Jumps: Stock Rises 6.8%
by Zacks Equity Research
Principia Biopharma (PRNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
BeiGene (BGNE) in Focus: Stock Moves 8.7% Higher
by Zacks Equity Research
BeiGene (BGNE) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Is Applied Therapeutics (APLT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (APLT) Outperforming Other Medical Stocks This Year?
Prothena (PRTA) Looks Good: Stock Adds 10.6% in Session
by Zacks Equity Research
Prothena (PRTA) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
89bio (ETNB) Jumps: Stock Rises 6.9%
by Zacks Equity Research
89bio (ETNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.